Skip Navigation
News and Publications
 
 
 
In This Section      
Print This Page

Conquest - CRF Inventions to the Marketplace

Making the Connection Update 2009-2010

CRF Inventions to the Marketplace

Date: May 1, 2010


Inventions by CRF investigators are moving discoveries from the laboratory to the marketplace:

  • An epigenetic test for colorectal cancer risk developed by Andrew Feinberg is licensed to Orion Genomics
  • Two research tools invented by Ben Ho Park for breast cancer discovery have been  licensed to Horizon Discovery
  • Patents are pending for Victor Velculescu’s first ever analysis of the tyrosine phosphatome, genes known to be good therapeutic targets in colorectal cancer
  • A novel therapeutic approach by Shyam Biswal addressing treatment resistance and tumor progression has been optioned to Quark and patents are pending in the U.S. and Canada
  • A patent is pending for Mary Armanios’ genetic test of telomere-associated genes. Telomeres are tiny protective caps on the end of chromosomes.  Shortened telomeres have been linked to cancer.

Other technologies developed by CRF investigators, include therapeutic compounds that block a cancer-related gene pathway called Nrf2, LigAmp, a sensitive test for detecting certain gene mutations, and a handheld patient education and decision support tool.

Related Content

Articles in this Issue

The CRF Supports a Decade of Cancer Research Advances

CRF Research Grants Fill Unmet Reasearch Funding

Essential Support for Young Faculty

CRF By the Numbers

 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer